LY 207702
Alternative Names: dFdAPLatest Information Update: 07 Jun 2001
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Deoxyadenosines; Small molecules
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 26 Aug 1996 Preclinical development for Cancer in USA (Unknown route)
- 22 Feb 1995 No-Development-Reported for Cancer in USA (Unknown route)